{"protocolSection":{"identificationModule":{"nctId":"NCT05982015","orgStudyIdInfo":{"id":"RICA-2"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Efficacy Study II on Remote Ischemic Preconditioning for the Prevention of Stroke-Associated Pneumonia","officialTitle":"Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Remote Ischemic Conditioning in Preventing Stroke-related Pneumonia","acronym":"RICA-2"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-01-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-08-01","studyFirstSubmitQcDate":"2023-08-01","studyFirstPostDateStruct":{"date":"2023-08-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-22","lastUpdatePostDateStruct":{"date":"2024-01-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Professor","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Verifying whether remote ischemic adaptation can reduce the occurrence of stroke related pneumonia in acute stroke patients within 24 hours of onset","detailedDescription":"Verifying whether remote ischemic adaptation can reduce the occurrence and safety of stroke related pneumonia in acute stroke patients within 24 hours of onset"},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1650,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention group","type":"EXPERIMENTAL","description":"Remote ischemic conditioning (RIC) -200mmHg and best medical management","interventionNames":["Device: Remote ischemic conditioning"]},{"label":"Sham group","type":"SHAM_COMPARATOR","description":"Remote ischemic conditioning (RIC) -60mmHg and best medical management","interventionNames":["Device: Sham remote ischemic conditioning"]}],"interventions":[{"type":"DEVICE","name":"Remote ischemic conditioning","description":"The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.","armGroupLabels":["Intervention group"]},{"type":"DEVICE","name":"Sham remote ischemic conditioning","description":"The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.","armGroupLabels":["Sham group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Stroke-associated pneumonia","description":"Stroke-associated pneumonia incidence rate","timeFrame":"7 days"}],"secondaryOutcomes":[{"measure":"Physician diagnosed pneumonia","description":"Physician diagnosed pneumonia incidence rate","timeFrame":"7 days"},{"measure":"Physician diagnosed pneumonia","description":"Physician diagnosed pneumonia incidence rate","timeFrame":"8-90 days"},{"measure":"Modified Rankin scale score from 0 to 1","description":"In medical and clinical research, the modified Rankin Scale (mRS) is used to assess the degree of disability in patients after a stroke. The scale ranges from 0 to 6, where 0 indicates no symptoms and 6 indicates death.\n\nOn the mRS scale, scores from 0 to 2 usually indicate no or slight disability. Specifically:\n\n0 points: No symptoms.\n\n1. point: Symptoms present but no significant disability; able to carry out all usual duties and activities.\n2. points: Slight disability; able to look after own affairs without assistance but unable to carry out all previous activities.\n\nTherefore, in clinical research, if a treatment or intervention increases the proportion of patients scoring 0 to 1 on the mRS scale, it is generally considered a positive outcome. This means that more patients have a better functional status and lower degree of disability after treatment.","timeFrame":"90 days after the onset of symptoms"},{"measure":"Modified Rankin scale score from 0 to 2","description":"In medical and clinical research, the modified Rankin Scale (mRS) is used to assess the degree of disability in patients after a stroke. The scale ranges from 0 to 6, where 0 indicates no symptoms and 6 indicates death.\n\nOn the mRS scale, scores from 0 to 2 usually indicate no or slight disability. Specifically:\n\n0 points: No symptoms.\n\n1. point: Symptoms present but no significant disability; able to carry out all usual duties and activities.\n2. points: Slight disability; able to look after own affairs without assistance but unable to carry out all previous activities.\n\nTherefore, in clinical research, if a treatment or intervention increases the proportion of patients scoring 0 to 2 on the mRS scale, it is generally considered a positive outcome. This means that more patients have a better functional status and lower degree of disability after treatment.","timeFrame":"90 days"},{"measure":"Modified Rankin scale scores","description":"Shift analysis. In medical and clinical research, the modified Rankin Scale (mRS) is used to assess the degree of disability in patients after a stroke. The scale ranges from 0 to 6, where 0 indicates no symptoms and 6 indicates death.\n\nOn the mRS scale, scores from 0 to 2 usually indicate no or slight disability. Specifically:\n\n0 points: No symptoms.\n\n1. point: Symptoms present but no significant disability; able to carry out all usual duties and activities.\n2. points: Slight disability; able to look after own affairs without assistance but unable to carry out all previous activities.\n\nTherefore, in clinical research, if a treatment or intervention increases the proportion of patients scoring 0 to 2 on the mRS scale, it is generally considered a positive outcome. This means that more patients have a better functional status and lower degree of disability after treatment.","timeFrame":"90 days"},{"measure":"EQ-5D-5L scores","description":"The scores of EQ-5D-5L. The five dimensions included in EQ-5D-5L are:\n\nMobility: This dimension assesses the person's ability to walk about. Self-Care: This evaluates the individual's ability to wash or dress themselves. Usual Activities: This covers work, study, housework, family or leisure activities.\n\nPain/Discomfort: This measures the level of pain or discomfort experienced by the individual.\n\nAnxiety/Depression: This assesses the person's psychological state, in terms of levels of anxiety or depression.\n\nEach of these five dimensions has five levels of severity:\n\nLevel 1: No problems Level 2: Slight problems Level 3: Moderate problems Level 4: Severe problems Level 5: Extreme problems","timeFrame":"90 days"},{"measure":"NIHSS stroke scale scores","description":"The scores of NIHSS stroke scale. The total NIHSS score can range from 0 to 42, with:\n\n0: Indicating no stroke symptoms. 1-4: Indicating a minor stroke. 5-15: Indicating a moderate stroke. 16-20: Indicating a moderate to severe stroke. 21-42: Indicating a severe stroke. The NIHSS is useful in evaluating the effect of acute stroke treatments, predicting patient outcomes, and assessing the progression of stroke symptoms.","timeFrame":"24 hours"},{"measure":"NIHSS stroke scale scores","description":"The scores of NIHSS stroke scale. The total NIHSS score can range from 0 to 42, with:\n\n0: Indicating no stroke symptoms. 1-4: Indicating a minor stroke. 5-15: Indicating a moderate stroke. 16-20: Indicating a moderate to severe stroke. 21-42: Indicating a severe stroke. The NIHSS is useful in evaluating the effect of acute stroke treatments, predicting patient outcomes, and assessing the progression of stroke symptoms.","timeFrame":"7 days"},{"measure":"Urinary tract infections","description":"Urinary tract infections incidence rate","timeFrame":"7 days"},{"measure":"Infections","description":"Infections incidence rate","timeFrame":"7 days"},{"measure":"All-cause mortality","description":"All-cause mortality incidence rate","timeFrame":"90 days"},{"measure":"Inpatient days","description":"Total inpatient days","timeFrame":"90 days"}],"otherOutcomes":[{"measure":"Spots of skin bleeding within 7 days","description":"Number of subjects who have skin bleeding points within 7 days","timeFrame":"7 days"},{"measure":"Red or swollen arms within 7 days","description":"Number of subjects who have red or swollen arms within 7 days","timeFrame":"7 days"},{"measure":"Dizziness within 7 days","description":"Number of subjects who have dizziness within 7 days","timeFrame":"7 days"},{"measure":"Nausea within 7 days","description":"Number of subjects who have nausea within 7 days","timeFrame":"7 days"},{"measure":"Palpitations within 7 days.","description":"Number of subjects who have palpitations within 7 days.","timeFrame":"7 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age≥18 years old;\n* Diagnosis of acute ischemic stroke;\n* Remote ischemic conditioning or sham-remote ischemic conditioning can be treated within 24 hours after stroke onset\n* NIHSS score≥4;\n* Subject or his or her legally authorized representative was able to provide informed consent.\n\nExclusion Criteria:\n\n* During the screening period, body temperature ≥ 38 ℃;\n* Evidence of lung infection, urinary tract infection or other infectious diseases during the screening period\n* Expected lifespan less than 7 days\n* Mechanical ventilation is expected to be required within 7 days;\n* Anti-infective drug were used within 7 days prior to stroke;\n* Uncontrolled hypertension with medication (defined as systolic blood pressure ≥200 mmHg and/or diastolic blood pressure ≥110 mmHg);\n* There are contraindications for remote ischemic conditioning (such as skin and soft tissue injury, fractures, peripheral arterial disease, etc. in the upper limbs);\n* History of autoimmune disease or malignancies;\n* Use of immunosuppressive drug within the preceding 3 months;\n* Pregnant or lactating, or pregnancy test positive;\n* Current participation in another investigational trial;\n* Other conditions are not suitable for this trial as evaluated by researchers.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xunming Ji, M.D. Ph.D","role":"CONTACT","phone":"861013120136877","email":"jixunming@vip.163.com; 1730812302@qq.com"},{"name":"Lina Jia, M.D.","role":"CONTACT","phone":"+8615901588600","email":"1730812302@qq.com"}],"overallOfficials":[{"name":"Chuanjie Wu, M.D.","affiliation":"Xuanwu Hospital of Capital Medical University","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Xunming Ji, M.D., Ph.D.","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"references":[{"pmid":"25612858","type":"BACKGROUND","citation":"Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, Kwa VI, Weisfelt M, Remmers MJ, ten Houten R, Schreuder AH, Vermeer SE, van Dijk EJ, Dippel DW, Dijkgraaf MG, Spanjaard L, Vermeulen M, van der Poll T, Prins JM, Vermeij FH, Roos YB, Kleyweg RP, Kerkhoff H, Brouwer MC, Zwinderman AH, van de Beek D, Nederkoorn PJ; PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015 Apr 18;385(9977):1519-26. doi: 10.1016/S0140-6736(14)62456-9. Epub 2015 Jan 20."},{"pmid":"26343840","type":"BACKGROUND","citation":"Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A, Rebollo-Mesa I; STROKE-INF Investigators. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet. 2015 Nov 7;386(10006):1835-44. doi: 10.1016/S0140-6736(15)00126-9. Epub 2015 Sep 3."},{"pmid":"27733675","type":"BACKGROUND","citation":"Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, Jungehulsing GJ, Montaner J, Bustamante A, Hermans M, Hamilton F, Gohler J, Malzahn U, Malsch C, Heuschmann PU, Meisel C, Meisel A; PREDICT Investigators. Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia - The PREDICT study. J Cereb Blood Flow Metab. 2017 Dec;37(12):3671-3682. doi: 10.1177/0271678X16671964. Epub 2016 Oct 14."},{"pmid":"22664787","type":"BACKGROUND","citation":"Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012 Jun 5;8(7):401-10. doi: 10.1038/nrneurol.2012.98."},{"pmid":"21738161","type":"BACKGROUND","citation":"Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011 Jul 7;17(7):796-808. doi: 10.1038/nm.2399."},{"pmid":"17255542","type":"BACKGROUND","citation":"Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke. 2007 Mar;38(3):1097-103. doi: 10.1161/01.STR.0000258346.68966.9d. Epub 2007 Jan 25."},{"pmid":"25176179","type":"BACKGROUND","citation":"Randhawa PK, Bali A, Jaggi AS. RIPC for multiorgan salvage in clinical settings: evolution of concept, evidences and mechanisms. Eur J Pharmacol. 2015 Jan 5;746:317-32. doi: 10.1016/j.ejphar.2014.08.016. Epub 2014 Aug 28."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000011014","term":"Pneumonia"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000012141","term":"Respiratory Tract Infections"},{"id":"D000007239","term":"Infections"},{"id":"D000008171","term":"Lung Diseases"},{"id":"D000012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M13594","name":"Pneumonia","asFound":"Pneumonia","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M9973","name":"Infections","relevance":"LOW"},{"id":"M6058","name":"Communicable Diseases","relevance":"LOW"},{"id":"M14668","name":"Respiratory Tract Infections","relevance":"LOW"},{"id":"M10858","name":"Lung Diseases","relevance":"LOW"},{"id":"M14667","name":"Respiratory Tract Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC01","name":"Infections"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}